Jubilant Life Sciences’ wholly-owned subsidiary -- Jubilant Pharma has redeemed the principal amount of $100 million on pro-rata basis out of $300 million notes at a redemption price of 102.43750% together with the accrued interest till date.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.